TCR2 Therapeutics Inc. [NASDAQ: TCRR] gained 33.88% or 0.41 points to close at $1.62 with a heavy trading volume of 19802246 shares. The company report on March 6, 2023 that Adaptimmune and TCR² Therapeutics Announce Strategic Combination to Create a Preeminent Cell Therapy Company for Solid Tumors.
From Robots to Self-Driving Cars: 5 AI Stocks to Consider for Your Portfolio
The artificial intelligence (AI) revolution is already here and it's about to change everything we know about everything. With the global market for AI projected to grow from $137 billion in 2022 to over $1.81 trillion by 2030, there's never been a better time to invest in this burgeoning industry. That's why we've compiled a list of the Top 5 AI Stocks to Buy for 2023. These companies are at the forefront of the AI revolution, and have the potential to deliver huge returns to investors like you.
Get our free report, "Top 5 AI Stocks to Buy for 2023".
Sponsored
Compelling clinical data with clear paths to products and multiple near‐term value-creating catalysts.
Complementary technology platforms designed to treat solid tumors which represents a substantial market opportunity largely unaddressed by cell therapies.
It opened the trading session at $1.55, the shares rose to $1.78 and dropped to $1.44, the range by which the price of stock traded the whole day. The daily chart for TCRR points out that the company has recorded -36.72% loss over the past six months. However, it is still -97.56% lower than its most recent low trading price.
If we look at the average trading volume of 270.40K shares, TCRR reached to a volume of 19802246 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here is what top equities market gurus are saying about TCR2 Therapeutics Inc. [TCRR]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for TCRR shares is $9.90 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on TCRR stock is a recommendation set at 2.30. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Goldman have made an estimate for TCR2 Therapeutics Inc. shares, keeping their opinion on the stock as Neutral, with their previous recommendation back on January 19, 2022. While these analysts kept the previous recommendation, Piper Sandler dropped their target price from $55 to $26. The new note on the price target was released on November 19, 2021, representing the official price target for TCR2 Therapeutics Inc. stock. Previously, the target price had yet another drop from $18 to $8, while SVB Leerink kept a Mkt Perform rating on TCRR stock. On September 17, 2021, analysts decreased their price target for TCRR shares from 45 to 11.
The Average True Range (ATR) for TCR2 Therapeutics Inc. is set at 0.14 The Price to Book ratio for the last quarter was 0.32, with the Price to Cash per share for the same quarter was set at 4.59.
Trading performance analysis for TCRR stock
TCR2 Therapeutics Inc. [TCRR] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 38.46. With this latest performance, TCRR shares gained by 17.39% in over the last four-week period, additionally sinking by -36.72% over the last 6 months – not to mention a drop of -35.97% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for TCRR stock in for the last two-week period is set at 68.47, with the RSI for the last a single of trading hit 74.22, and the three-weeks RSI is set at 64.44 for TCR2 Therapeutics Inc. [TCRR]. The present Moving Average for the last 50 days of trading for this stock 1.2288, while it was recorded at 1.3120 for the last single week of trading, and 2.0065 for the last 200 days.
TCR2 Therapeutics Inc. [TCRR]: A deeper dive into fundamental analysis
Return on Equity for this stock declined to -38.53, with Return on Assets sitting at -35.05.
TCR2 Therapeutics Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 5.00 and a Current Ratio set at 5.00.
TCR2 Therapeutics Inc. [TCRR]: An earnings per share (EPS) analysis
The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for TCRR. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for TCR2 Therapeutics Inc. go to 0.00%.
An analysis of insider ownership at TCR2 Therapeutics Inc. [TCRR]
There are presently around $34 million, or 66.00% of TCRR stock, in the hands of institutional investors. The top three institutional holders of TCRR stocks are: MPM ASSET MANAGEMENT LLC with ownership of 4,050,865, which is approximately 0% of the company’s market cap and around 1.40% of the total institutional ownership; BIOIMPACT CAPITAL LLC, holding 3,370,982 shares of the stock with an approximate value of $5.46 million in TCRR stocks shares; and TANG CAPITAL MANAGEMENT LLC, currently with $4.44 million in TCRR stock with ownership of nearly -26.798% of the company’s market capitalization.
Positions in TCR2 Therapeutics Inc. stocks held by institutional investors increased at the end of Monday and at the time of the Monday reporting period, where 21 institutional holders increased their position in TCR2 Therapeutics Inc. [NASDAQ:TCRR] by around 1,382,144 shares. Additionally, 48 investors decreased positions by around 5,568,861 shares, while 18 investors held positions by with 14,275,029 shares. The mentioned changes placed institutional holdings at 21,226,034 shares, according to the latest SEC report filing. TCRR stock had 6 new institutional investments in for a total of 60,407 shares, while 24 institutional investors sold positions of 2,884,486 shares during the same period.